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Editorial on the Research Topic
Multi-Target-Directed Ligands (MTDL) as Challenging Research Tools in Drug Discovery:
From Design to Pharmacological Evaluation
The philosophy “one molecule—one target—one disease” was the dominant approach in medicinal
chemistry for several decades up till the end of the twentieth century. This strategy was based on
the identification and optimization of small chemical entities able to recognize specifically one
target, believed to be fully responsible for a certain disease. The aim of the “one drug-one target”
approach was to find bioactive compounds endowed with a limited risk of off-target properties,
many times responsible for drug side-effects. This philosophy started to change in the last 20 years
due to the emergent growing awareness that drugs designed to act on individual molecular targets
are usually inadequate for multigenic diseases such as cancer, neurodegenerative, and infectious
diseases (Ramsay et al., 2018). System biology and omic sciences recently enriched the knowledge
of the complex world underlying their pathogenesis, depicting the importance of networked
signaling pathways and suggesting multi-target therapeutics as potentially more advantageous than
mono-therapies. Nowadays, so called “drug-cocktails” are often the only available approaches to
pharmacologically treat many of these pathologies, with concerns related to drug-drug interactions
as well as to patients’ compliance. Hence, it is appropriate and relevant to search for novel bioactive
compounds able to combine in one molecule multi-target properties, according to the paradigm of
“network pharmacology” (Hopkins, 2008).
Therefore, a special issue dedicated to collect research activities from critical areas for the
development of novel multi-target-directed ligands (MTDL) through the close cooperation among
pharmacologists, biochemists, medicinal chemists, and toxicologists, has been proposed. This
research topic should collect new approaches developed to overcome the main issues faced by
medicinal chemists in the design, synthesis, and biological evaluation of these promising, but
extremely challenging, new chemical entities. The first is the identification of new MTDL derived
either from natural sources or synthetic procedures. The second is related to the-state-of-the-art
biological and biophysical tests particularly suited to rapidly explore a multi-target profile.
The third concerns the creation of chemoinformatic tools such as a chemical database for the
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collection and management of multi-target agents. The fourth
is dedicated to advanced methods for the in silico estimation of
multi-target ligands by means of docking and virtual screening
tools. The contribution submitted by Oliveira et al. deals
with the design and synthesis of new multitarget compounds
that target mitochondrial oxidative stress (OS) and restore
cholinergic transmission. The new molecules show favorable
toxicological profile, neuroprotective activity, and drug-like
properties, thus suggesting a fine blood-brain barrier (BBB)
permeability. All together, these results indicate that the
anticholinesterase inhibition coupled with antioxidant properties
is an effective therapeutic strategy for Alzheimer’s disease
(Oliveira et al.) Another contribution was submitted by Elshaflu
et al. In this case, the proposed ligands were able to inhibit
monoaminooxidase (MAO) isoforms based on the isosteric
replacement (S − > Se) within the (1,3-thiazol-2-yl)hydrazine
scaffold. This chemical manipulation induced an improvement of
antioxidant properties. Moreover, in-silico calculations of ADME
properties showed good pharmacokinetic profiles of some
compounds investigated. The manuscript submitted by Albreht
et al. deals with the clarification of the mechanism of action of
MTDLs containing the propargylamine as the reactive moiety
toward MAO cofactor. In this paper, a rational design of efficient
new generation drugs for the treatment of neurodegenerative
and neuropsychiatric disorders is suggested (Albreht et al.). The
manuscript from Koch et al. focused on MAO inhibition as co-
target together with human A1 and A2A adenosine receptors
(ARs). The study deals with the synthesis and in vitro evaluation
of novel annelated xanthine derivatives. The multitarget activity
of such compounds paves the way to a potential application
for the treatment of neurodegenerative diseases, in particular
Parkinson’s disease (Koch et al.). The manuscript submitted by
Ortuso et al. explicitly discussed the creation of a chemical
database and the implementation of the Chemotheca platform,
the networking tool specifically useful for speeding up the
multi-target drug discovery process (Ortuso et al.). In another
contribution, by Yosipof et al. a chemical database was also
used to carry out the proposed in silico work (Yosipof et al.).
Machine learning methods were applied in a multi-target fashion
to distinguish drug and non-drugs for three different classes of
compounds. The ability to use such tools for the identification of
interesting trends opens up new opportunities for understanding
the factors affecting drug performance and for designing new
drugs. Another interesting manuscript collected in this research
topic is that by Roman et al. which discussed in silico approaches
to predict also antitarget and physicochemical profiles of (S)-
blebbistatin, the best-known myosin II ATPase inhibitor, and a
series of analogs (Roman et al.). This paper is a good example
concerning the use of in silico techniques which should be useful
for accelerating the discovery of new molecules with appropriate
target and antitarget profiles. Finally, the paper by Pagano
et al. is an interesting publication related to multi-targeting
agents able to recognize DNA in multiple non-canonical
conformations, typically folding as a G-quadruplex motif
(Pagano et al.).
In conclusion, this research topic launched in January 2018
and closed in April 2018 has gathered contributions from design,
synthesis, and biological evaluation of multi-target molecules.
This research topic has covered most of the competencies
encompassed in such a modern and stimulating field of drug
discovery. We are aware that it is far more complex than what
this research topic can capture, but we wish we can contribute
to add pieces to the puzzle of rational and effective multi-target
drug discovery.
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